hiv

HIV-1 TAT (48-60) Acetate, a commonly used membrane-permeable carrier peptide, is an arginine-rich basic peptide derived from the human immunodeficiency virus (HIV-1 Tat) protein that enables intracellular delivery of compounds.

DAPTA (Adaptavir) is an inhibitor of CCR5, shows potent anti-HIV activities.

FC131 TFA (606968-52-9 free base) (FC131 TFA) is an antagonist of CXCR4 that inhibits the binding of [125I] -sdf-1 to CXCR4(IC50 : 4.5 nM ), and has anti-hiv activity.

TAT peptide (YGRKKRRQRRR), originating from the human immunodeficiency virus-1 (HIV-1) transactivator of transcription (TAT), enhances the solubility and production of heterologous proteins[1]. This cell-penetrating peptide demonstrates significant potential in biotechnological applications.

HIV-1 Rev (34-50) (HIV-1 rev Protein (34-50)) is a 17-amino acid peptide with anti-HIV-1 activity, derived from the Rev-responsive element-binding domains of Rev in HIV-1.

HIV Protease Substrate 1 is a fluorogenic compound that offers insights into the enzymatic activity of HIV protease, making it a valuable tool for studying this aspect.

(Cys47)-HIV-1 tat Protein (47-57) possesses membrane translocation functionality and can serve as a surface derivatization agent for magnetic pharmaceuticals, enhancing their uptake into specific target cells.

HIV-1 TAT (48-60), a cell-penetrating peptide originating from residues 48-60 of the human immunodeficiency virus (HIV)-1 Tat protein, facilitates the non-disruptive delivery of exogenous macromolecules into cells.

HIV Protease Substrate 1 TFA, a fluorogenic substrate for HIV protease, facilitates the investigation of the enzyme's activity [1].

HIV Protease Substrate I, a chromogenic substrate for HIV-1 protease, contains the protease's cleavage site [1].

Fluorescent HIV Substrate (HIV substrate)

HIV-1, HIV-2 Protease Substrate serves as a substrate for the proteases of both HIV-1 and HIV-2, featuring four residues that permit conservative substitutions at the enzyme substrate binding sites [1].

HIV Protease Substrate IV, a substrate for HIV (human immunodeficiency virus) protease, facilitates the measurement of HIV-1 protease activity [1].

GP120, HIV-1 MN, a peptide, is utilized in researching HIV infection [1] [2].

HIV-IN peptide is a competitive inhibitor of HIV-1 protease (K i = 50 nM) [1].

Pol (476-484), HIV-1 RT Epitope, is a biologically active peptide representing the dominant HLA A*0201-restricted epitope within HIV-1 reverse transcriptase (RT). Spanning Pol residues 476-484, it is utilized to explore mechanisms of HIV-1 escape from cytotoxic T lymphocytes (CTL) with IV9 as the specific epitope processed and presented in HIV-1-infected cell lines.

HIV gag peptide (197-205) is an H-2Kd-restricted epitope derived from the p24 portion of the HIV-1 gag protein, composed of amino acids 197-205 (AMQMLKETI).

HIV p17 Gag (77-85) is an attractive target for molecular intervention due to its involvement in the viral replication cycle at both pre- and postintegration levels. In current experiments, we targeted p17 by intracellularly expressing a cDNA encoding an Ab to p17.

MPG, a 27-amino acid peptide compound, is derived from the fusion peptide domain of HIV-1 gp41 and the nuclear localisation sequence of SV40 large T antigen. As a potent delivery agent, MPG enables efficient and widespread transport of nucleic acids and oligonucleotides into cultured cells.

HIV-1 TAT (48-60) is a cell-penetrating peptide derived from the human immunodeficient virus (HIV)-1 Tat protein residue 48-60. This is one of the cell-penetrating peptides generated from the human immunodeficient virus -1 Tat protein residue 48-60.

HIV-1 tat Protein (1-9) is a polypeptide molecule with the sequence MDPVDPNIE.

R15K, HIV-1 Inhibitory Peptide is a polypeptide molecule with the sequence RIQRGPGRAFVTIGK.

HIV-1 gag Protein p24 (194-210) is a polypeptide molecule with the sequence ANPDCKTILKALGPAAT.

HIV-1 env Protein gp41 (1-23) amide (isolates BRU JRCSF) is a polypeptide molecule with the sequence AVGIGALFLGFLGAAGSTMGARS-NH2.